微生物群与肺癌的早期诊断及辅助治疗

Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer

肺癌患者在治疗过程中出现的耐药和不良反应依然是现代医学难题。研究表明肠道和肺部微生物群的丰度、多样性和代谢产物等可用于辅助肺癌的早期诊断和预后监测。同时,肠道微生物群还可以联合化疗、免疫治疗及靶向治疗等作为综合治疗的手段,增强疗效并减轻其不良反应。微生物群已在肺癌的诊疗中呈现出广阔的应用前景。

Drug-resistance and adverse reaction in the treatment of lung cancer patients are still a difficult problem in modern medicine.Studies have indicated that the abundance,diversity and metabolites of intestinal and pulmonary microbiota can be used to assist in the early diagnosis and monitoring the prognosis of lung cancer.Meanwhile,as combined modality therapies,intestinal microbiota combined with chemotherapy,immunotherapy and targeted therapy can enhance therapeutic effect and reduce adverse reaction.Microbiota exhibits an extensive application prospect in the diagnosis and treatment of lung cancer.